Zynerba Pharmaceuticals

A clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs

Learn More

Our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, Fragile X syndrome, fibromyalgia and peripheral neuropathic pain through synthetic cannabinoid therapeutics formulated for transdermal delivery.

Our Team

Our Team

Our team has a proven track record of success in developing novel transdermal products for patients in need.

More >>

Our Development Pipeline

Our Development Pipeline

We are developing two proprietary products: a transdermal synthetic CBD gel for refractory epilepsy, osteoarthritis and Fragile X syndrome and a novel synthetic THC pro-drug transdermal patch for two pain indications – fibromyalgia and peripheral neuropathic pain.

More >>

For Investors

For Investors

Learn more about our company and our potential.

More >>

Latest News

0327

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights

Learn More

0313

Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017

Learn More